Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Samsara Biocapital
BioCentury | Dec 19, 2024
Emerging Company Profile
Ottimo: Differentiating from the VEGF bispecific pack via VEGFR-2
Newco, led by ex-Seagen CEO Epstein, announces $140M series A
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Nov 8, 2024
Finance
Neurogene draws $200M PIPE ahead of next week’s Rett syndrome data
In BioCentury’s Finance Report: Travere’s follow-on, CrossBridge’s seed round among few fundings during quiet election week
BioCentury | Nov 8, 2024
Deals
With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger
Samsara-backed start-up launched by former Genentech colleagues picks AlloVir as vehicle to reach NASDAQ
BioCentury | Oct 25, 2024
Management Tracks
Chinook veterans join Jade
Plus: Apnimed hires Ramzi Benamar as CFO and an update from PhotonPharma
BioCentury | Oct 19, 2024
Finance
Cash raises for Inventiva, Akeso, Capricor
Public Equity Report: French biotech to fund MASH study with €348M lifeline; bispecifics developer raises $250; DMD cardiomyopathy play prices follow-on
BioCentury | Oct 15, 2024
Management Tracks
Jonathan Dickinson at the helm of Innate
Plus: Sernova hires CFO and updates from Inventiva
BioCentury | Sep 19, 2024
Finance
Series A cash for Brenus, GCTx, Nura among week’s VC highlights
Also in BioCentury’s latest Venture Report: New investment initiatives from Novo and RA Capital
BioCentury | Sep 12, 2024
Finance
Venture Report: Big rounds for Candid, Superluminal, PanTera
Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G
BioCentury | Sep 10, 2024
Emerging Company Profile
Candid: Bispecifics for autoimmunity, leveraging Chinese oncology innovation
Ken Song’s post-RayzeBio venture pulled together two licensing deals, an M&A transaction and three financings totaling $370M
Items per page:
1 - 10 of 141